Ersilia Lucenteforte
Overview
Explore the profile of Ersilia Lucenteforte including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
145
Citations
2375
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Passaro M, Kilic D, Virgili G, Romano V, Lucenteforte E, Dick B, et al.
Br J Ophthalmol
. 2025 Feb;
PMID: 40015940
Aims: Refractive lens exchange (RLE) is becoming a popular refractive solution for patients ineligible for corneal surgeries or phakic intraocular lenses. However, concerns regarding retinal detachment (RD) risk persist. Methods:...
2.
Lopes S, Servadio M, Spini A, LAbbate L, Ingrasciotta Y, Giometto S, et al.
Expert Opin Biol Ther
. 2024 Dec;
25(1):119-131.
PMID: 39668420
Background: Monitoring biologic drug therapy during pregnancy in women with immune-mediated inflammatory diseases (IMIDs) is crucial to ensure treatments align with evidence-based practices. Research Design And Methods: A retrospective cohort...
3.
Ferraro S, Cappello E, Fornili M, Convertino I, Bonaso M, Lucenteforte E, et al.
Drug Saf
. 2024 Nov;
48(3):217-231.
PMID: 39514152
Background: In 2018, the European Medicines Agency issued some risk minimisation measures related to unresolved adverse drug reactions (ADRs) reported for fluoroquinolones, including sensory ADRs. Spontaneous reporting databases frequently report...
4.
DAlessandro C, Giannese D, Ruisi M, Pellegrino N, Lucenteforte E, Panichi V, et al.
Kidney Blood Press Res
. 2024 Oct;
49(1):978-986.
PMID: 39433040
Introduction: Nutrition and physical activity are two major issues in the management of CKD patients who are often older, have comorbidities, and are prone to malnutrition and physical inactivity, conditions...
5.
Piragine E, Malanima M, Ceccanti C, Guidi L, Martelli A, Lucenteforte E, et al.
Phytother Res
. 2024 Sep;
38(12):5765-5781.
PMID: 39343737
Dyslipidemia is a risk factor for cardiovascular diseases. Preclinical studies have shown that organosulfur compounds from the Alliaceae and Brassicaceae plants, such as garlic (Allium sativum L.) and broccoli (Brassica...
6.
Parri N, Giacalone M, Greco M, Aceti A, Lucenteforte E, Corsini I
Acta Paediatr
. 2024 Sep;
114(1):156-163.
PMID: 39310951
Aim: The aim of this study is to describe circumstances, management and short-term outcomes of neonatal head trauma, and adherence to the Paediatric Emergency Care Applied Research Network (PECARN) head...
7.
Trambusti I, Barba C, Mortilla M, Rizzi S, Romano K, Coniglio M, et al.
Front Immunol
. 2024 Sep;
15:1422802.
PMID: 39221243
Aims: Early detection and treatment of neurodegenerative Langerhans cell histiocytosis (ND-LCH) have been suggested to prevent neurodegenerative progression. The aim of the study is to validate a standardized multidisciplinary diagnostic...
8.
Marino M, Rosa A, Finocchietti M, Bellini A, Poggi F, Massari M, et al.
Front Transplant
. 2024 Jul;
1:1060621.
PMID: 38994384
Background: In immunosuppression after transplantation, several multi-drug approaches are used, involving calcineurin inhibitors (), antimetabolites (), mammalian target of rapamycin inhibitors (), and corticosteroids. However, data on immunosuppressive therapy by...
9.
Giugni C, Cecchi C, Giometto S, Lucenteforte E, Mondardini C, Chiusolo F, et al.
Pediatr Transplant
. 2024 Jun;
28(5):e14806.
PMID: 38923333
Background: Italy presently does not have a pediatric organ donation program after cardiocirculatory determination of death (pDCDD). Before implementing a pDCDD program, many centers globally have conducted studies on the...
10.
Ceccarelli L, Moretti G, Mazzilli S, Petri D, Corazza I, Rizzo C, et al.
BMC Infect Dis
. 2024 Mar;
24(1):362.
PMID: 38553731
This comprehensive retrospective data-linkage study aimed at evaluating the impact of Direct-Acting Antivirals (DAAs) on Hepatitis C Virus (HCV) testing, treatment trends, and access to care in Tuscany over six...